Skip to content

Author

Lin Xu

We have 2 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

AI-driven dual-task prediction model for co-stratifying efficacy and toxicity in NSCLC immunotherapy

While effective against non-small cell lung cancer (NSCLC), PD-1 inhibitors can induce immune-related adverse events (irAEs), occurring in up to 15.2% of patients and potentially fatal. Currently, effective predictive biomarkers capable of simultaneously forecasting both irAEs and immune checkpoint inhibitor (ICI) resp...

Hanlin Ding, Yu-Ting Ren, Siqi Ding et al. · 0 citations
Open access Jul 2026

Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis.

BACKGROUND Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality worldwide, with limited treatment options due to inherent chemotherapy resistance. Ferroptosis, an iron-dependent form of regulated cell death, has recently emerged as a promising strategy to overcome this resistance. Inducing ferropto...

Zedong Sun, Minmin Zhou, Can Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.